Observation on clinical effects of acupoint thread-embedding method for non-alcoholic fatty liver disease

穴位埋线治疗非酒精性脂肪性肝病临床疗效观察（英文）

Objective： To observe the clinical effects of acupoint thread-embedding method for non-alcoholic fatty liver disease （NAFLD） in pattern of liver qi stagnation and spleen deficiency. Methods： A total of 180 cases in conformity with the diagnostic criteria of NAFLD in pattern of liver qi stagnation and spleen deficiency were randomly divided into a treatment group and a control group, 90 cases in each group, and finally 88 cases in the treatment group and 90 cases in the control group were recruited for statistics. The treatment group was managed by acupoint thread-embedding method, and the control group was treated by oral administration of Polyene Phosphatidylcholine capsules. Both groups were treated for 6 months. Before and after the treatment, liver enzymology, blood fat test, abdominal B ultrasonic examination, and assessment of clinical effects were respectively processed. Results： After treatment, alanine transaminase （ALT）, aspartate transaminase （AST）, total cholesterol （TC）, and triglyceride （TG） decreased in the treatment group, and were significantly different from those in the control group after treatment （all P〈0.05）. There was no statistically significant inter-group difference in the degree of fatty liver （by B ultrasound examination） before treatment （P〉0.05）. After treatment, the improvement degree of fatty liver in the treatment group was more significant than that in the control group （P〈0.05）. The total effective rates were 89.8% in the treatment group and 76.7% in the control group, with a statistically significant difference between the two groups （P〈0.05）. Conclusion： The acupoint thread-embedding method can reduce the levels of ALT, AST, TC and TG in NAFLD patients, and can improve the pathologic degree of fatty liver and its clinical effects are remarkably better than that of oral medications.

目的:观察穴位埋线对肝郁脾虚证型非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的临床疗效。方法:将180例符合纳入标准的肝郁脾虚证型NAFLD患者随机分为治疗组和对照组,每组90例,最终纳入统计治疗组88例,对照组90例。治疗组采用局部穴位埋线,对照组给予口服多烯磷酯酰胆碱胶囊,两组均治疗6个月,治疗前后分别检测肝脏酶学及血脂检测、腹部B超及评价两组临床疗效。结果:治疗后治疗组血清谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶(aspartate transaminase,AST)、总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)水平均较本组治疗前下降,且与对照组治疗后差异有统计学意义(均P<0.05)。治疗前两组患者腹部B超检查显示脂肪肝的程度接近,差异无统计学意义(P>0.05);治疗后治疗组脂肪肝的改善程度较对照组显著,组间差异有统计学意义(P<0.05)。治疗组总有效率为89.8%,对照组为76.7%,组间差异有统计学意义(P<0.05)。结论:穴位埋线可降低NAFLD患者ALT、AST、TC和TG水平,显著改善脂肪肝病变程度,且临床疗效显著优于口服药物。